Loading organizations...
§ Private Profile · Cambridge, United Kingdom
clinical-stage oncology biopharmaceutical company developing bicyclic peptides: targeted cytotoxics, radioligand therapies.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of chemically synthesized peptide medicines for oncology applications, based in Cambridge, United Kingdom, with a US headquarters in Lexington, Massachusetts. The publicly traded enterprise focuses on creating targeted cytotoxics, innate immune activators, and radioligand therapies designed to treat solid tumors. Operating with over 300 employees, the firm maintains a market capitalization of approximately $1.5 billion and recently secured $555 million in a May 2024 private investment in public equity financing. The company advances its internal pipeline alongside strategic development partnerships with major pharmaceutical corporations, including AstraZeneca, Novartis, Bayer, and Genentech. These collaborations include a targeted radioligand agreement with Novartis that featured a $50 million initial upfront payment. Bicycle Therapeutics was founded in 2009 by Nobel Laureate Sir Gregory Winter and Professor Christian Heinis.
Bicycle Therapeutics has raised $651.0M across 5 funding rounds.
Bicycle Therapeutics has raised $651.0M in total across 5 funding rounds.
Bicycle Therapeutics has raised $651.0M in total across 5 funding rounds.
Bicycle Therapeutics's investors include Deep Track Capital, EcoR1 Capital, Fairmount, Forbion, Perceptive Advisors, RA Capital Management, Christopher Shen, Abingworth, Advent Life Sciences, Atlas Venture, EQT Life Sciences, Hatteras Venture Partners.
Bicycle Therapeutics has raised $651.0M across 5 funding rounds. Most recently, it raised $555.0M Other Equity in May 2024.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing Bicycle® molecules, a novel class of precision-guided therapeutics designed to target intractable diseases, primarily solid tumor cancers.[1][2] These fully synthetic bicyclic peptides combine the pharmacological properties of biologics with the manufacturing and pharmacokinetic advantages of small molecules, enabling deep tissue penetration, high affinity binding, and conjugation to payloads like toxins or radioisotopes.[1][3][4] The company serves patients with hard-to-treat cancers and explores applications beyond oncology, such as anti-infectives and cardiovascular diseases, addressing unmet needs through a pipeline of Bicycle Toxin Conjugates (BTCs), tumor-targeted immune cell agonists (TICAs), and radioconjugates.[1][3][5] Growth momentum is driven by multiple assets in clinical trials, strategic pharma partnerships, and non-dilutive funding for expanded research, positioning Bicycle to commercialize transformative medicines.[2][3]
Bicycle Therapeutics was founded in 2009 based on pioneering research by Sir Greg Winter, a Nobel Prize-winning scientist, and Professor Christian Heinis, who developed bicyclic peptides as a new therapeutic modality.[2][3] The idea emerged from advancing peptide constraints into stable, high-affinity structures capable of mimicking protein-protein interactions that small molecules couldn't target.[2][4] Early years focused on perfecting the technology, industrializing synthesis, and identifying oncology applications, evolving from proof-of-concept to precision tumor-targeting agents.[2] Pivotal moments include building a transatlantic presence with headquarters in Cambridge, UK, and operations in Boston, USA; securing Innovate UK funding for antimicrobial resistance research; and rapidly advancing SARS-CoV-2 inhibitors in 2020 via UK Research & Innovation support.[3] This foundation has led to a robust clinical pipeline today.[5]
Bicycle Therapeutics stands out through its proprietary Bicycle® platform, which generates versatile, chemically synthesized peptides (1.5-2.5kDa) constrained into bicyclic loops for superior target engagement.[1][4]
Bicycle Therapeutics rides the wave of next-generation precision oncology, targeting solid tumors resistant to traditional small molecules or antibodies amid rising demand for tissue-penetrating therapies.[1][2] Timing aligns with advances in peptide engineering and conjugation tech, fueled by market forces like antimicrobial resistance crises (no new antibiotic classes in 50+ years) and post-pandemic urgency for rapid-response platforms, as shown in their SARS-CoV-2 work.[3] The company influences the ecosystem by pioneering a new therapeutic class—bridging biologics and small molecules—enabling bespoke partnerships and non-dilutive funding models that accelerate innovation in underserved areas like CNS and neuromuscular diseases.[1][3] This positions Bicycle as a key player in diversifying the biotech toolbox beyond monoclonal antibodies.
Bicycle Therapeutics is poised for milestone-driven growth with clinical readouts from its BTC, TICA, and radioconjugate pipeline, potentially leading to approvals and commercialization in solid tumors.[5] Key trends like multimodal conjugates, AI-accelerated discovery, and expansion beyond oncology (e.g., dementia, respiratory) will shape its trajectory, bolstered by pharma alliances.[1][2] Influence may evolve from tech pioneer to leading solid tumor player, transforming patient outcomes if trials validate superior efficacy and safety—echoing their founding vision of precision-guided medicines for the largest possible populations.[1]